Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis related interstitial lung disease

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100054220

Enrollment

Unknown

Registered

2021-12-11

Start date

2021-12-04

Completion date

Unknown

Last updated

2022-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis related interstitial lung disease

Interventions

Tofacitinib group:No

Traditional immunosuppressive therapy group:No

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Patients with RA-ILD met the relevant classification criteria of RA-ILD: conforming to two or more of the following three items and confirmed by respiratory physicians: (1) Chest radiograph or chest high-resolution CT (HRCT) shows ILD image changes; (2) Lung function test suggests restrictive ventilatory dysfunction (TLC <= 80%); (3) Bronchoscopy or surgical lung biopsy confirmes ILD; 2. Subclinical RA-ILD patients, met the 2010 American College of Rheumatology/European Union against Rheumatism (ACR/EULAR) RA classification criteria.

Exclusion criteria

Exclusion criteria: 1. Cardiac insufficiency; 2. Other connective tissue diseases.

Design outcomes

Primary

Measure	Time frame
Disease activity score 28-joint count CRP (DAS28-CRP);Pulmonary function test (PFT);HRCT(High Resolution CT) Warrick's Assessment;	—

Countries

Chian

Contacts

Public ContactXie Weilin

Yantai Yuhuangding Hospital

403253755@qq.com+86 15954511828

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026